Artwork

Content provided by MediCom Oncology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MediCom Oncology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Enasidenib in mutant-IDH2 R/R AML: Results of a phase 1 dose-escalation and expansion study

8:26
 
Share
 

Manage episode 188136589 series 1375096
Content provided by MediCom Oncology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MediCom Oncology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Dr. Eytan Stein provides a brief update on phase 1 arms of a trial studying the effectiveness of enasidenib in patients with relapsed and refractory AML and an IDH2 mutation.
  continue reading

53 episodes

Artwork
iconShare
 
Manage episode 188136589 series 1375096
Content provided by MediCom Oncology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MediCom Oncology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Dr. Eytan Stein provides a brief update on phase 1 arms of a trial studying the effectiveness of enasidenib in patients with relapsed and refractory AML and an IDH2 mutation.
  continue reading

53 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide